DoseCraft
VapeHeatLabRescheduling
Moving cannabis to a lower drug schedule under the Controlled Substances Act while keeping it federally regulated.
Rescheduling means moving cannabis from its current Schedule I classification to a lower schedule within the Controlled Substances Act, acknowledging its medical value while maintaining some level of federal regulatory control. The most discussed proposal would move cannabis to Schedule III, which includes drugs like testosterone, ketamine, and Tylenol with codeine.
The Rescheduling Process
In 2022, President Biden directed HHS to review cannabis scheduling. In 2023, HHS recommended rescheduling to Schedule III based on scientific and medical evidence. In 2024, the DEA published a proposed rule to implement this change, triggering a public comment period and administrative law proceedings. The process is historically slow: the last major rescheduling action for any drug took years to complete. Cannabis rescheduling would be the most significant change to federal drug policy in decades.
What Schedule III Would Mean
Moving cannabis to Schedule III would have several practical impacts. Section 280E tax penalties would no longer apply, potentially saving the industry billions annually. FDA-approved cannabis research would become easier to conduct. The change would signal federal acknowledgment of cannabis's medical value. However, Schedule III still requires DEA registration for manufacturers and FDA oversight for medical products, creating potential tensions with existing state market structures. For many advocates, rescheduling to Schedule III is a welcome step but still falls short of the descheduling that would fully resolve federal-state conflicts.